PYPD
Price:
$3.33
Market Cap:
$22.66M
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.[Read more]
Industry
Biotechnology
IPO Date
2020-06-26
Stock Exchange
NASDAQ
Ticker
PYPD
According to PolyPid Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -0.38. This represents a change of -34.34% compared to the average of -0.58 of the last 4 quarters.
The mean historical PE Ratio of PolyPid Ltd. over the last ten years is 1.31. The current -0.38 PE Ratio has changed -3001.78% with respect to the historical average. Over the past ten years (40 quarters), PYPD's PE Ratio was at its highest in in the June 2019 quarter at 215.56. The PE Ratio was at its lowest in in the March 2019 quarter at -51.35.
Average
1.31
Median
-2.66
Minimum
-30.31
Maximum
53.19
Discovering the peaks and valleys of PolyPid Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 24.57%
Maximum Annual PE Ratio = 53.19
Minimum Annual Increase = -1487.90%
Minimum Annual PE Ratio = -30.31
Year | PE Ratio | Change |
---|---|---|
2023 | -0.22 | -34.82% |
2022 | -0.34 | -87.00% |
2021 | -2.64 | -1.72% |
2020 | -2.69 | -105.05% |
2019 | 53.19 | 24.57% |
2018 | 42.70 | -1487.90% |
2017 | -3.08 | -79.09% |
2016 | -14.71 | -51.45% |
2015 | -30.31 | 5.25% |
2013 | -28.80 | -79.60% |
The current PE Ratio of PolyPid Ltd. (PYPD) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.07
5-year avg
9.46
10-year avg
1.31
PolyPid Ltd.’s PE Ratio is greater than Cue Biopharma, Inc. (-1.59), greater than Anixa Biosciences, Inc. (-8.95), greater than INmune Bio, Inc. (-3.06), greater than IN8bio, Inc. (-0.43), less than eFFECTOR Therapeutics, Inc. (-0.00), greater than Landos Biopharma, Inc. (-5.74), less than Apexigen, Inc. (-0.36), less than Navidea Biopharmaceuticals, Inc. (0.01), less than Angion Biomedica Corp. (-0.24), greater than Anebulo Pharmaceuticals, Inc. (-5.95), greater than Armata Pharmaceuticals, Inc. (-1.27), less than Virpax Pharmaceuticals, Inc. (-0.08), greater than Vaccitech plc (-2.49), greater than Virax Biolabs Group Limited (-0.68), less than Blue Water Vaccines, Inc. (-0.17), less than Revelation Biosciences, Inc. (-0.09), less than Hillstream BioPharma, Inc. (-0.00), less than Kiora Pharmaceuticals, Inc. (4.79), greater than Pyxis Oncology, Inc. (-3.88), greater than Zura Bio Limited (-10.87), less than Altamira Therapeutics Ltd. (-0.03), greater than Elevation Oncology, Inc. (-0.78),
Company | PE Ratio | Market cap |
---|---|---|
-1.59 | $89.71M | |
-8.95 | $111.02M | |
-3.06 | $138.58M | |
-0.43 | $14.26M | |
-0.00 | $1.88K | |
-5.74 | $71.68M | |
-0.36 | $9.57M | |
0.01 | $50.04K | |
-0.24 | $30.11M | |
-5.95 | $49.01M | |
-1.27 | $85.03M | |
-0.08 | $3.47M | |
-2.49 | $192.73M | |
-0.68 | $8.86M | |
-0.17 | $3.41M | |
-0.09 | $3.19M | |
-0.00 | $4.17M | |
4.79 | $10.92M | |
-3.88 | $225.81M | |
-10.87 | $278.69M | |
-0.03 | $1.96M | |
-0.78 | $30.89M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like PolyPid Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like PolyPid Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is PolyPid Ltd.'s PE Ratio?
How is the PE Ratio calculated for PolyPid Ltd. (PYPD)?
What is the highest PE Ratio for PolyPid Ltd. (PYPD)?
What is the 3-year average PE Ratio for PolyPid Ltd. (PYPD)?
What is the 5-year average PE Ratio for PolyPid Ltd. (PYPD)?
How does the current PE Ratio for PolyPid Ltd. (PYPD) compare to its historical average?